The global lung cancer surgery market is on a steady growth trajectory, with an expected increase from USD 1.48 billion in 2025 to USD 2.64 billion by 2035, reflecting a Compound Annual Growth Rate (CAGR) of 5.9%. This growth is driven by a combination of factors, including improved early detection through low-dose CT screening, increased access to care through government-backed programs, and rising awareness, particularly as high-profile public figures share their cancer journeys.
Lung cancer remains a significant global health issue, with major case loads in countries like China, the United States, Japan, and India. As these nations improve early diagnosis, surgical intervention rates are steadily increasing, bolstering the demand for advanced treatment options.
Unlock detailed analytics – Request your personalized report now! https://www.futuremarketinsights.com/reports/sample/rep-gb-396
Key Drivers Fueling Market Expansion
Lung cancer surgeries are increasingly focused on precision, minimally invasive procedures that integrate cutting-edge technologies such as robotic-assisted systems, artificial intelligence (AI), and image-guided tools. “Advancements in robotic-assisted thoracic procedures are redefining precision and patient recovery in oncology,” said Gary Guthart, CEO of Intuitive Surgical, in 2024. The technology is not only enhancing precision but is also improving post-operative recovery times.
Olympus Corporation’s launch of AI-enhanced imaging systems in 2024 has further propelled the market, allowing clinicians to correlate intraoperative visuals with long-term outcomes. As robotic systems are expected to account for over 40% of lung cancer surgeries by 2035, hospitals are becoming key players in the market, particularly with robotic-assisted procedures.
Competitive Landscape and Market Leaders
The lung cancer surgery market is moderately consolidated, with key players such as Intuitive Surgical, Medtronic, Ethicon (Johnson & Johnson), Olympus, and Karl Storz leading the industry.
- Intuitive Surgical holds a market share of approximately 22-24%, thanks to its dominance in robotic-assisted thoracic surgeries with its flagship da Vinci platform.
- Medtronic follows with a 18-20% share, bolstered by its extensive global distribution and a wide array of advanced surgical instruments.
- Ethicon (J&J), with an estimated 16-18% share, excels in comprehensive surgeon training programs and advanced energy devices for thoracic surgeries.
- Olympus and Karl Storz, with 10-12% and 8-10% market shares respectively, focus on visualization systems and endoscopic technologies that enhance diagnostic precision and support early cancer detection.
These players continue to innovate and expand, forming strategic alliances and offering tailored solutions that improve patient outcomes. With the ongoing push toward digital integration and AI-driven surgery, these companies are well-positioned for future market dominance.
Country-Specific Market Insights
- United States: The U.S. remains the largest market for lung cancer surgeries, expected to grow from USD 420 million in 2025 to USD 620 million by 2035. Government-backed initiatives and early screening programs, particularly low-dose CT scans, have improved early-stage detection, ensuring that more patients are eligible for surgical interventions.
- China: China ranks as the second-largest market, with a projected value of USD 1.12 billion by 2025, growing at a CAGR of 6.7%. With the highest lung cancer incidence globally, the government’s Healthy China 2030 agenda is driving significant investments in early detection and surgery, boosting the demand for advanced thoracic surgical systems.
- India: India’s market is expected to grow at the fastest pace, with a projected CAGR of 7.0%. The increasing prevalence of lung cancer, especially in urban areas, and the expanding availability of advanced diagnostic tools and surgical infrastructure are contributing to a strong market outlook.
Market Segments: Segmentectomy and Hospitals Lead
Among various surgical techniques, segmentectomy holds a significant 40.1% market share, particularly due to its lung-sparing advantages. This minimally invasive procedure is gaining traction among patients with early-stage non-small cell lung cancer (NSCLC), especially in aging populations. As early detection programs expand, segmentectomy’s share is projected to grow at a CAGR of 5.5% from 2025 to 2035.
In terms of end-users, hospitals dominate the market, accounting for 65.0% of the market share. Hospitals are equipped with advanced surgical infrastructure, including robotic-assisted systems, and offer multidisciplinary teams capable of handling complex surgeries and post-operative care. As robotic-assisted surgeries gain popularity, hospitals are expected to maintain their leading role, experiencing a projected CAGR of 5.8%.
Download Brochure for Full Insights: https://www.futuremarketinsights.com/reports/brochure/rep-gb-396
Future Outlook
As healthcare systems increasingly prioritize precision surgery, lung cancer surgery is moving towards minimally invasive, technology-driven approaches. The integration of robotic systems, AI, and advanced imaging tools is transforming the landscape, improving outcomes and patient recovery times.
The market will continue to be driven by the expansion of early detection programs, governmental healthcare policies aimed at improving access to care, and rising public awareness. However, challenges remain, such as the cost of advanced technologies and disparities in healthcare access, particularly in rural regions.
With continued advancements in surgical techniques, digital integration, and increased access to care, the global lung cancer surgery market is poised for significant growth, offering opportunities for investment and innovation in the coming years.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
